VIDEO – Novamind Discusses Partnership with Merck for New Treatment-Resistant Depression Trial

Last week Novamind (NM: CSE:) (NVMDF: OTC) (HN2: FSE) announced  that its wholly-owned subsidiary, Cedar Clinical Research has been  selected as a key research site for a clinical trial focused on  treatment-resistant depression by Merck & Co., a world-leading  pharmaceutical company.  The phase II study will assess the  efficacy and safety of a new Merck drug for treatment-resistant  depression (TRD), a mental health condition that affects approximately  30% of people who suffer from major depressive disorder. Yaron Conforti, CEO and Director of  Novamind said: "Under Dr. Robison's leadership, Cedar Clinical Research  has proven itself as a best-in-class research site for emerging mental  health therapeutics. We're excited to work with Merck, a world-class  pharmaceutical company, to advance research for innovative mental health  treatments." Sit back, relax and watch this powerful interview with Yaron Conforti, CEO and Director of Novamind.